FDA grants Priority Review to ViiV Healthcare's New Drug Application for cabotegravir long-acting for prevention of HIV Pharmaceutical Investing
Gilead Marks Fifth Approval for Trodelvy® in Metastatic Triple-Negative Breast Cancer Under Project Orbis Initiative with Health Canada Authorization Biotech Investing
Americans are Frustrated by Unexpected Blurry Near Vision Issues, a New Survey Reveals Biotech Investing
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Applications for Opdivo + Yervoy and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Biotech Investing
Merck Announces KEYTRUDA® Met Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib Pharmaceutical Investing
Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults Pharmaceutical Investing
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency Pharmaceutical Investing
Knight Therapeutics Inc. places No. 27 on The Globe and Mail's third-annual ranking of Canada's Top Growing Companies Medical Device Investing
LYNPARZA® in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless of Biomarker Status in PROpel Phase 3 Trial in First-Line Metastatic Castration-Resistant Prostate Cancer Pharmaceutical Investing
Pfizer Invites Public to View and Listen to Webcast of Pfizer November 2 Conference Call with Analysts Pharmaceutical Investing
